MedTrace Logo

MRD Assay Evaluates Recurrence and Response Via a Tumor Informed Assessment

NCT05219734 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2024-03-12

No results posted yet for this study

Summary

This study recruits patient with solid tumor types for sample collection and monitoring. Participants will provide blood and archival tissue samples in order to create a Personalized Cancer Monitoring (PCM) assay. This assay will be used to detect circulating tumor DNA (ctDNA) levels in the blood over time and hopefully contribute to improvements in residual disease detection methods for future patients.

Results from this assay will be provided to participants and providers but providers are not asked to change patient care based on this information.

Conditions

Interventions

DIAGNOSTIC_TEST

Personalized Cancer Monitoring (PCM)

personalized molecular test for solid tumor cancer patients that may detect the presence of circulating tumor DNA (ctDNA) and molecular residual disease (MRD), also known as minimal residual disease

Sponsors & Collaborators

  • Invitae Corporation

    lead INDUSTRY

Principal Investigators

  • Ed Esplin, MD, PhD · Invitae Corporation

  • Michael Korn · Invitae Corporation

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-29
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05219734 on ClinicalTrials.gov